# An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

> **NCT00686088** · PHASE2 · COMPLETED · sponsor: **Sophiris Bio Corp** · enrollment: 30 (estimated)

## Conditions studied

- Locally Recurrent Prostate Cancer

## Interventions

- **DRUG:** PRX302

## Key facts

- **NCT ID:** NCT00686088
- **Lead sponsor:** Sophiris Bio Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686088, "An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00686088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*